Table 1.
Demographic and clinical characteristics of subjects enrolled.
| All patients (n = 16) | Patients who underwent T2 (n = 7) | Healthy subjects (n = 14) | |
|---|---|---|---|
| Sex | 6M/10F | 3M/4F | 7M/7F |
| Age, years | 44.0 ± 12.4 | 43.6 ± 10.7 | 41.1 ± 9.8 |
| Interval onset-EDX, days | 16.0 ± 12.0 | 12.9 ± 5.5 | - |
| VAS-O (T0) | 8.7 ± 2.4 | 8.4 ± 2.8 | - |
| HRS (T0) | 26.2 ± 6.6 | 25.7 ± 7.7 | - |
| VAS-G (T0) | 7.3 ± 4.0 | 6.7 ± 4.7 | - |
| CiTAS (T0) | 28.8 ± 12.3 | 28.4 ± 14.2 | - |
| VAS-O (T1) | 2.4 ± 3.7 | 2.4 ± 4.2 | - |
| HRS (T1) | 13.2 ± 9.5 | 12.0 ± 10.4 | - |
| VAS-G (T1) | 2.7 ± 3.9 | 2.4 ± 4.2 | - |
| CiTAS (T1) | 15.5 ± 11.4 | 14.4 ± 12.3 | - |
| VAS-O (T2) | - | 0.6 ± 1.5 | - |
| HRS (T2) | - | 7.7 ± 4.5 | - |
| VAS-G (T2) | - | 0.6 ± 1.5 | - |
| CiTAS (T2) | - | 10.3 ± 6.0 | - |
Data are reported as number of patients or mean values ± SD.
CiTAS, Chemotherapy Induced Taste Alteration Scale; EDX, electrodiagnostic examination; HRS, Hyposmia Rating Scale; T0, baseline assessment; T1, 1-month follow-up; T2, 20-month follow-up; VAS-G, Gustatory Visual Analog Scale; VAS-O, Olfactory Visual Analog Scale.